Market is Price

I was deep into fumbling my way through this piece when a comment from Farhan Zaidi’s end of the year comments / press gaggle attached to the official announcement by the San Francisco Giants of the Taylor Rogers signing popped up on my glitchy Twitter timeline: For me, whether it’s in season or offseason, there are ups and downs. Part of the fun is getting off the mat and living to fight another day. I still believe in this team and this organization. I’m still excited about the moves we can still make. I’m really looking forward to seeing what this team looks like come spring training. [...] So I really hope our fans stick with us as we kind of work through some of what’s happened this offseason. And continue to work for the next couple months. Call me a weirdo, but that sounds like the Giants aren’t done making moves. Does that mean more bites of the free agency-flavored apple? That all depends on what the Giants might be looking for: a left-handed hitter with on base and

NEW YORK, Dec 30 (Reuters) - Drugmakers including Pfizer Inc (PFE.N) , GlaxoSmithKline PLC (GSK.L) , Bristol Myers Squibb (BMY.N) , AstraZeneca PLC (AZN.L) and Sanofi SA (SASY.PA) plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors. The increases are expected to come as the pharmaceutical industry prepares for the Biden Administration's Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices directly for some drugs starting in 2026. The industry is also contending with inflation and supply chain constraints that have led to higher manufacturing costs. The increases are on list prices, which do not include rebates to pharmacy benefit managers and other discounts. In 2022, drugmakers raised prices on more than 1,400 drugs according to data published

2022 0% S&P 500 −20 Crypto Emerging markets −40 The Year the Long Stock Market Rally Ended How fast inflation and high interest rates upended markets across the globe. Karl Russell and Joe Rennison has spent a decade reporting on markets. Karl Russell and John-Michael Murphy pored through years of stock and market data to visualize trends for this article. Dec. 30, 2022 Jan. 3, the first day of market trading in 2022, looked like just another day in a stock rally that began when Barack Obama was still president. The S&P 500 hit a record high. Tesla , the company that upturned the auto industry and made many investors rich, rose 13.5 percent and came close to its own all-time peak. That Monday, it turned out, was actually the end of a market that for over a decade had gone mostly in one direction, with the S&P 500 rising more than 600 percent since March 2009. Just two days later, the Federal Reserve rel

Crypto holders had a rough ride in 2022. At the start of the year, the collective market cap of cryptocurrencies worldwide stood at $2.2 trillion. As the year ends, that figures stands at just below $800 billion. The industry's euphoric highs of last year descended into a bear market of epic proportions, leaving many of the industry's major players in collapse. Or worse. The plunge in crypto prices started with central banks cutting the cord on easy money policies, which dragged down risky assets first, and the problems multiplied from there — accounts were frozen, bankruptcies declared, frauds uncovered. As Yahoo Finance's Jared Blikre pointed out , whether in spite of crypto’s epic swoon or because of it, Yahoo Finance's bitcoin ( BTC-USD ) quote page took the eighth spot on this year's top trending ticker page behind major stock indices like the S&P 500, Dow, and Nasdaq, and three megacap stocks: Tesla, Apple, and Amazon. In 2021, cryptocurrencies power